Selarsdi Injection, Solution
Product Images NDC 50090-7769

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Selarsdi (NDC 50090-7769). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Image 1)

An instructional diagram of an injection syringe showing labeled parts including the plunger, plunger head, needle guard activation clips, needle guard wings, body, viewing window, label, needle, and needle cover, depicting components of a subcutaneous injection device.*

FDA Label Image

Image (Image 10)

An instructional diagram labeled Figure F showing a hand holding a syringe for subcutaneous injection at a 45-degree angle to the skin, indicated by an arrow and an angle marker. The image illustrates proper injection technique for SELARSDI (ustekinumab-aekn) 90 mg/mL injection, solution.*

FDA Label Image

Image (Image 11)

An instructional illustration depicting the use of a subcutaneous injection device with a syringe labeled for SELARSDI (ustekinumab-aekn). It shows a hand holding the device at an injection site on skin, highlighting the proper positioning for administering the injection.*

FDA Label Image

Image (Image 12)

An instructional illustration showing a hand administering a subcutaneous injection using a syringe. The image demonstrates the syringe insertion into the skin, with another hand stabilizing the injection site.*

FDA Label Image

Image (Image 13)

An instructional illustration showing a hand holding a cotton ball or pad, pressing it onto the back of another hand's finger. The image is labeled as Figure I and appears to demonstrate a step in a procedure or application technique.*

FDA Label Image

Image (Image 14)

An instructional illustration showing a device with a plunger and needle cap being positioned above a red and white container filled with liquid, accompanied by a downward arrow indicating insertion or dipping action. The figure is labeled 'Figure J' and likely depicts preparation steps for subcutaneous injection of SELARSDI (ustekinumab-aekn).*

FDA Label Image

A (Image 15)

An instructional illustration labeled Figure A showing six items arranged horizontally: an adhesive bandage, antiseptic wipes in a sealed square packet, cotton ball or gauze pads, a vial labeled Selarsdi, a syringe with an attached needle, and a red FDA-cleared sharps disposal container with an open lid.*

FDA Label Image

B (Image 16)

Illustration showing recommended subcutaneous injection sites for SELARSDI (ustekinumab-aekn) 90 mg/mL solution. Injection areas highlighted in orange include the front of the thigh, the outer area of the upper arm, and the lower abdomen or buttocks.*

FDA Label Image

C (Image 17)

An instructional illustration labeled 'Figure C' showing a vial with liquid and a cap being removed by lifting or twisting upwards, indicated by an orange curved arrow.*

FDA Label Image

D (Image 18)

An instructional illustration labeled Figure D showing two hands opening a vial by lifting the cap upwards. The vial is held steadily in one hand while the other hand lifts the cap, indicated by an upward curved arrow.*

FDA Label Image

E (Image 19)

An instructional illustration depicting a person using both hands to remove the cap from a syringe. One hand holds the syringe while the other pulls the cap straight off, indicated by double-headed arrows showing the pulling motion.*

FDA Label Image

Image (Image 2)

An instructional illustration showing the subcutaneous injection technique where a syringe is held perpendicular to the skin, preparing to administer an injection. The image highlights proper hand positioning and needle angle for injecting a solution under the skin.*

FDA Label Image

F (Image 20)

An instructional illustration labeled Figure F showing two hands preparing a syringe by drawing solution from a vial. One hand holds the vial steady while the other hand pulls the plunger of the syringe upward to withdraw the liquid.*

FDA Label Image

G (Image 21)

Illustration showing hands drawing liquid from a vial into a syringe, likely demonstrating preparation of an injectable solution for subcutaneous administration.*

FDA Label Image

H (Image 22)

An instructional illustration showing hands preparing a subcutaneous injection. One hand holds a vial inverted, while the other hand draws liquid into a syringe. The image demonstrates the technique of filling the syringe with medication from the vial.*

FDA Label Image

I (Image 23)

An instructional diagram showing the proper technique for subcutaneous injection. It depicts a hand holding a syringe at a 45-degree angle to the skin, with another hand stabilizing the injection site.*

FDA Label Image

J (Image 24)

An instructional illustration showing a hand holding a syringe with an arrow pointing to the thumb, indicating proper technique for administering a subcutaneous injection.*

FDA Label Image

Image (Image 3)

An instructional illustration showing a hand administering a subcutaneous injection using a prefilled syringe. The image depicts insertion of the needle under the skin at an angle appropriate for subcutaneous delivery, demonstrating proper injection technique.*

FDA Label Image

1 (Image 4)

A line graph showing patient response percentages over 24 weeks for three groups: placebo, ustekinumab 45 mg, and ustekinumab 90 mg. The x-axis represents weeks (0 to 24), and the y-axis represents the percentage of patients (0 to 60%). Ustekinumab groups show higher patient response rates compared to placebo throughout the study period.*

FDA Label Image

Image (Image 5)

An instructional diagram of a prefilled syringe showing its components: plunger head, plunger, needle guard activation clips, needle guard wings, body, viewing window, label, needle, and needle cover. The syringe appears designed for subcutaneous injection.*

FDA Label Image

Image (Image 6)

Illustration labeled Figure B showing items for injection administration and disposal: an adhesive bandage, antiseptic wipes, a cotton ball or gauze pad, a SELARSDI prefilled syringe, and an FDA-cleared sharps disposal container.*

FDA Label Image

Image (Image 7)

An instructional illustration labeled Figure C showing recommended subcutaneous injection sites highlighted in yellow. Sites indicated include the front and outer thigh, the lower abdomen near the waistline, the upper arm, and the upper buttocks area. The diagrams depict front, side, and rear views of a human body to guide appropriate injection locations.*

FDA Label Image

Image (Image 8)

Illustration showing hands removing a needle cap from a prefilled syringe or injection device, indicated by an upward arrow, as part of instructions for preparing an injection. The image is associated with SELARSDI 90 mg/mL ustekinumab-aekn subcutaneous injection.*

FDA Label Image

Image (Image 9)

Illustration showing a hand holding a subcutaneous injection device, labeled as Figure E. The image depicts the correct grip and positioning for administering an injection with the device, consistent with the administration method of SELARSDI (ustekinumab-aekn) 90 mg/mL solution for injection.*

FDA Label Image

Label Image (Lbl500907769)

SELARSDI 90 mg/mL injection, solution for subcutaneous use, by A-S Medication Solutions. The label includes the product NDC 50090-7769 and states each milliliter delivers 90 mg of ustekinumab-aekn. Packaging instructions indicate storage in a refrigerator at 2 to 8 degrees Celsius and feature a single-dose prefilled syringe with 0.90 mL strength. Additional labeling includes manufacturer location and a QR code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.